We aspire to utilize innovative approaches to discover new therapies that support cardiac regeneration and repair.

Velakor Biotherapeutics was founded as a Cambrian Bio incubated company in 2021 by Velakor’s scientific co-founders Prof. Eldad Tzahor, Ph.D. and Kfir Umansky, Ph.D. Professor Tzahor’s team at the Weizmann Institute of Science discovered that an extracellular matrix proteoglycan called Agrin can restore heart tissues’ neonatal capability to regenerate and self-repair in mice.
‍
Velakor has secured exclusive global rights to develop CAM-6019 for cardiac regeneration and repair. CAM-6019 is an Agrin-derived biologic therapy that has demonstrated successful cardiac regeneration and repair in translatable, porcine models of ST elevated myocardial infarction (STEMI) and heart failure with reduced ejection fraction (HFrEF).